Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to -$422.8 million.

  • Cardiff Oncology's Retained Earnings fell 1354.0% to -$422.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$422.8 million, marking a year-over-year decrease of 1354.0%. This contributed to the annual value of -$384.2 million for FY2024, which is 1314.66% down from last year.
  • Cardiff Oncology's Retained Earnings amounted to -$422.8 million in Q3 2025, which was down 1354.0% from -$411.6 million recorded in Q2 2025.
  • Cardiff Oncology's Retained Earnings' 5-year high stood at -$236.7 million during Q1 2021, with a 5-year trough of -$422.8 million in Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$320.5 million (2023), whereas its average is -$322.5 million.
  • As far as peak fluctuations go, Cardiff Oncology's Retained Earnings crashed by 1046.03% in 2021, and later crashed by 1576.64% in 2022.
  • Cardiff Oncology's Retained Earnings (Quarter) stood at -$259.8 million in 2021, then dropped by 14.74% to -$298.1 million in 2022, then dropped by 13.9% to -$339.5 million in 2023, then fell by 13.15% to -$384.2 million in 2024, then fell by 10.06% to -$422.8 million in 2025.
  • Its Retained Earnings stands at -$422.8 million for Q3 2025, versus -$411.6 million for Q2 2025 and -$397.6 million for Q1 2025.